Author:
Murai Kazuki,Katsuno Tomoyuki,Miyagawa Jun-ichiro,Matsuo Toshihiro,Ochi Fumihiro,Tokuda Masaru,Kusunoki Yoshiki,Miuchi Masayuki,Namba Mitsuyoshi
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Japanese Ministry of Health, Labour and Welfare. National Health and Nutrition Survey, 2007 [in Japanese]. http://www.mhlw.go.jp/bunya/kenkou/eiyou09/dl/01-kekka.pdf . Accessed Aug 2014.
2. International Diabetes Federation. IDF diabetes atlas. 5th ed. Brussels: International Diabetes Federation; 2011.
3. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
4. Herman GA, Mistry GC, Yi B, Bergman AJ, Wang AQ, Zeng W, et al. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol. 2011;71:429–36.
5. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study Group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e20–2.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献